Chronic fatigue — whether as CFS/ME, post-viral fatigue, or adrenal-immune exhaustion — involves mitochondrial dysfunction, persistent low-grade inflammation, HPA axis dysregulation, and immune activation that collectively drain cellular and systemic energy reserves. Peptide research targets mitochondrial efficiency, immune normalization, and the neuroendocrine dysfunction driving persistent exhaustion.
1. BPC-157 — HPA Axis / Mitochondrial Support
BPC-157 modulates the hypothalamic-pituitary-adrenal axis, reducing the pathological cortisol dysregulation common in chronic fatigue states. It also supports mitochondrial function via nitric oxide pathway modulation and reduces the systemic inflammation that imposes metabolic “taxation” on cellular energy systems.
Dosing Protocol: 250–500 mcg SubQ daily, or 500 mcg oral (arginate form) to address gut-driven inflammatory fatigue. Cycle: 8–12 weeks.
2. Thymosin Alpha-1 — Immune Normalization
CFS and post-viral fatigue often involve persistent immune activation — the immune system stuck in a “fighting” state that chronically draws energy. Thymosin Alpha-1 normalizes Th1/Th2/Th17 balance, resolves chronic low-grade immune activation, and reduces the inflammatory cytokine burden that directly causes fatigue symptoms.
Dosing Protocol: 1.5 mg SubQ twice weekly for 4 weeks, then 1.5 mg once weekly. Cycle: 8–12 weeks.
3. MOTS-C — Mitochondrial Energetics
MOTS-C directly activates AMPK and enhances mitochondrial efficiency — effectively improving the energy output per unit of metabolic substrate. In fatigue states characterized by mitochondrial dysfunction, MOTS-C can meaningfully improve cellular energy availability and physical endurance capacity.
Dosing Protocol: 5–10 mg SubQ 3–5x per week. Best timed around midday to avoid sleep disruption. Cycle: 4–8 weeks.
4. Epithalon — Circadian Rhythm / Telomere Support
Chronic fatigue is often compounded by disrupted circadian rhythms and accelerated cellular aging. Epithalon (Epitalon) normalizes melatonin secretion from the pineal gland, restores circadian sleep-wake cycles, and has demonstrated telomere-lengthening effects that reduce the cellular senescence burden contributing to fatigue.
Dosing Protocol: 5–10 mg SubQ daily for 10 days. Rest 30–60 days before repeating. Some protocols use 2x per year cycles.
BPC-157 addresses the HPA dysregulation and gut-driven inflammation perpetuating fatigue while Thymosin Alpha-1 resolves the immune activation chronically taxing energy reserves. MOTS-C directly improves mitochondrial energy output and MOTS-C handles cellular energetics. Epithalon restores the circadian melatonin rhythm needed for restorative sleep and cellular repair.
- Seiwerth S et al. (2018). BPC-157 multi-system effects. Peptides.
- Goldstein AL et al. (2018). Thymosin alpha-1 immune modulation. Int Immunopharmacol.
- Lee C et al. (2023). MOTS-C and mitochondrial metabolism. Nature Medicine.
- Khavinson VKh et al. (2003). Epithalon and pineal regulation. Neuroendocrinology Letters.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).